Page 1 - CIMA SCS Workbook November 2018 - Day 1 Suggested Solutions
P. 1

Day 1 Suggested Solutions




                  Chapter 11




                  SUGGESTED SOLUTIONS










                  CHAPTER TWO - QUIZ

                  Question                                  Your response

                      1. How many factories does Novak      12 factories in 10 countries – p.17
                         operate, and in how many
                         countries?

                      2. Which is the biggest global        Horter – p.3
                         pharmaceutical company by
                         revenue?

                      3. In what year did Novak become a    1960 – p.9
                         quoted company?

                      4. Who is the Director of Finance at  Randal Edwards – p.14
                         Novak?

                      5. How has Novak’s share price        It has fallen by roughly 1/3, from around
                         performed over the last 5 years?   $450/share to just below $300 – p.24

                      6. Who does Novak sell pharmaceutical  Larger pharmacies, such as those in larger
                         products to?                       hospitals and major chains of retail pharmacists;
                                                            and also to specialist wholesalers who then supply
                                                            smaller pharmacies – p.11

                      7. How many acquisitions did Novak    3 – p.12
                         make last year?
                      8. Which pharmaceutical company has   Werstra – p.25
                         developed Denovax?

                      9. What percentage of its earnings did  89% (9,000/10,117) – p.19
                         Novak pay out as a dividend for the
                         year to 31.12.2017?

                      10. What is the value of the global sales  More than US$1,100 billion – p.3
                         of pharmaceutical products?
                      11. What is the main focus of the PRA?  The budgetary implications of approving a new
                                                            drug – p.8




                  KAPLAN PUBLISHING                                                                    41
   1   2   3   4   5   6